LONDON and PHILADELPHIA – September 4, 2026 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces that it has received an accelerated payment notice from the convertible bond holder in respect of the April 2026 quarterly deferred convertible bond repayment, which the Company has elected to settle in cash.
Accordingly, the Company has settled the accelerated quarterly amortization payment of £2.613 million, representing principal of £2.4 million together with the associated interest and fees payable in the deferment. Following the cash settlement of the April 2026 quarterly deferred convertible bond repayment, both deferred payments have now been satisfied.
After settlement of this deferred quarterly repayment and the July 2026 scheduled payment, both made in cash, the principal remaining under the convertible bond will be reduced to £12.0 million, representing ~3.8% of the market capitalization of the Company.